Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis:post-hocanalysis from the phase III, double-blind, placebo- and active-comparator-controlled VOYAGE 1/2 trials

被引：6

作者：

Youn, Sang Woong ^{[1
,2
]}

Yu, Dae Young ^{[3
,4
]}

Kim, Tae Yoon ^{[5
]}

Kim, Byung Soo ^{[6
]}

Lee, Seung Chul ^{[7
]}

Lee, Jeung Hoon ^{[8
]}

Choe, Yong-Beom ^{[9
]}

Lee, Joo-Heung ^{[10
]}

Choi, Jee-Ho ^{[11
]}

Roh, Joo Young ^{[12
]}

Jo, Seong Jin ^{[13
]}

Lee, Eun-So ^{[14
]}

Shin, Min Kyung ^{[15
]}

Lee, Min-Geol ^{[16
]}

Jiang, Jingzhi ^{[17
]}

Lee, YoungJa ^{[3
]}

机构：

[1] Seoul Natl Univ, Dept Dermatol, Bundang Hosp, 82 Gumi Ro 173 Beon Gil, Seongnam 13620, Gyeonggi, South Korea

[2] Seoul Natl Univ, Coll Med, Seongnam, South Korea

[3] Janssen Korea Ltd, Med Affairs, Seoul, South Korea

[4] Korea Univ, Dept Publ Hlth, Coll Med, Seoul, South Korea

[5] Catholic Univ Korea, Dept Dermatol, Seoul St Marys Hosp, Seoul, South Korea

[6] Pusan Natl Univ, Dept Dermatol, Sch Med, Busan, South Korea

[7] Chonnam Natl Univ Hosp, Dept Dermatol, Gwangju, South Korea

[8] Chungnam Natl Univ Hosp, Dept Dermatol, Daejeon, South Korea

[9] Konkuk Univ, Dept Dermatol, Sch Med, Seoul, South Korea

[10] Sungkyunkwan Univ, Samsung Med Ctr, Dept Dermatol, Sch Med, Seoul, South Korea

[11] Univ Ulsan, Asan Med Ctr, Dept Dermatol, Coll Med, Seoul, South Korea

[12] Gachon Univ, Gil Med Ctr, Dept Dermatol, Coll Med, Incheon, South Korea

[13] Seoul Natl Univ, Dept Dermatol, Coll Med, Seoul, South Korea

[14] Ajou Univ Hosp, Dept Dermatol, Suwon, South Korea

[15] Kyung Hee Univ, Dept Dermatol, Med Ctr, Seoul, South Korea

[16] Yonsei Univ, Severance Hosp, Dept Dermatol, Coll Med, Seoul, South Korea

[17] Janssen Res & Dev LLC, Spring House, PA USA

来源：

JOURNAL OF DERMATOLOGICAL TREATMENT | 2022年 / 33卷 / 01期

关键词：

Psoriasis; interleukin-23; VOYAGE; 1; 2; MONOCLONAL-ANTIBODY; PLAQUE PSORIASIS; EPIDEMIOLOGY; SECUKINUMAB; USTEKINUMAB; NATIONWIDE; DISEASE;

D O I：

10.1080/09546634.2020.1770174

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background:The phase 3 studies, VOYAGE 1 and 2, were conducted to assess guselkumab in the treatment of patients with moderate-to-severe psoriasis. Objectives:To investigate the efficacy and safety of guselkumab in Korean patients. Methods:The Korean sub-population of VOYAGE 1 and 2 study patients were included in this analysis. Efficacy and safety were evaluated through Weeks 24 and 28, respectively. Results:Of 126 randomized Korean patients, 30, 63, and 33 received placebo, guselkumab, and adalimumab, respectively. At Week 16, guselkumab was superior to placebo in achieving an Investigator's Global Assessment (IGA) score of 0 or 1 (cleared or minimal; 90.5 vs. 20.0%,p<.001) and a Psoriasis Area and Severity Index (PASI) 90 response (71.4 vs. 3.3%,p<.001). At week 24, a significantly higher proportion of guselkumab-treated patients achieved PASI 75 and IGA 0 (clear skin) responses compared to adalimumab-treated patients (PASI 75: 93.7 vs. 66.7%,p<.001; IGA 0: 52.4 vs. 21.2%,p=.004). Through Week 28, guselkumab and adalimumab showed comparable safety profiles. Conclusion:The efficacy and safety of guselkumab in Korean psoriasis patients through 28 weeks were consistent with findings for the overall VOYAGE 1 and 2 study population.

引用

页码：535 / 541

页数：7

共 50 条

[41] Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
Burden, A. David
Bissonnette, Robert
Navarini, Alexander A.
Murakami, Masamoto
Morita, Akimichi
Haeufel, Thomas
Ye, Binqi
Baehner, Frank
Terui, Tadashi
DERMATOLOGY AND THERAPY, 2023, 13 (10) : 2279 - 2297
[42] Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study
Van Voorhees, Abby S.
Gold, Linda Stein
Lebwohl, Mark
Strober, Bruce
Lynde, Charles
Tyring, Stephen
Cauthen, Ashley
Sofen, Howard
Zhang, Zuoshun
Paris, Maria
Wang, Yao
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (01) : 96 - 103
[43] Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study
Ebisawa, Motohiro
Kataoka, Yoko
Tanaka, Akio
Nagao, Mizuho
Laws, Elizabeth
Mortensen, Eric
Nawata, Hisakatsu
Arima, Kazuhiko
Watanabe, Daisuke
Lu, Xin
Maloney, Jennifer
Dubost-Brama, Ariane
Bansal, Ashish
Yahata, Kenji
ALLERGOLOGY INTERNATIONAL, 2024, 73 (04) : 532 - 542
[44] Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Wallace, Daniel J.
Kalunian, Kenneth
Petri, Michelle A.
Strand, Vibeke
Houssiau, Frederic A.
Pike, Marilyn
Kilgallen, Brian
Bongardt, Sabine
Barry, Anna
Kelley, Lexy
Gordon, Caroline
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 183 - 190
[45] Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials
Kim A. Papp
April W. Armstrong
Kristian Reich
Mahinda Karunaratne
Wendell Valdecantos
American Journal of Clinical Dermatology, 2016, 17 : 79 - 86
[46] Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study
Igarashi, Atsuyuki
Katsunuma, Toshio
Matsumura, Takayo
Komazaki, Hiroshi
BRITISH JOURNAL OF DERMATOLOGY, 2023, 190 (01) : 20 - 28
[47] A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients With Active Ankylosing Spondylitis
Peters, Eric
Chou, Richard C.
Rozzo, Stephen J.
Yao, Siu-Long
Fructuoso, Ferran Jose Garcia
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023, 29 (05) : 223 - 229
[48] Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
Krueger, James G.
Ferris, Laura K.
Menter, Alan
Wagner, Frank
White, Alexander
Visvanathan, Sudha
Lalovic, Bojan
Aslanyan, Stella
Wang, Elaine E. L.
Hall, David
Solinger, Alan
Padula, Steven
Scholl, Paul
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 136 (01) : 116 - U231
[49] Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients
de Souza, Savio Bastos
Cabral, Paula Gebe Abreu
da Silva, Renato Martins
Arruda, Raul Ferraz
Cabral, Sheila Passos de Figueiredo
de Assis, Aricia Leone Evangelista Monteiro
Viana Junior, Antonio Brazil
Degrave, Wim Maurits Sylvain
Moreira, Aline dos Santos
Silva, Cleber Gloria
Chang, Junbiao
Lei, Pingsheng
FRONTIERS IN MEDICINE, 2023, 10
[50] Efficacy and Safety of Mirogabalin (DS-5565) for the Treatment of Diabetic Peripheral Neuropathic Pain: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Adaptive Proof-of-Concept Phase 2 Study
Vinik, Aaron
Rosenstock, Julio
Sharma, Uma
Feins, Karen
Hsu, Ching
Merante, Domenico
DIABETES CARE, 2014, 37 (12) : 3253 - 3261

← 1 2 3 4 5 →